Market closed · After hours · 6:14 PM ET
Last update: Oct 5, 2026, 6:13 PM ET
Vaxcyte, Inc.
$73.82▲ 30.70% today
After Hours

Why Vaxcyte, Inc. (PCVX) stock moved

Updated Oct 5, 2026

Vaxcyte, Inc. (PCVX) shares climbed 30.7% to $73.82 as of October 5, 2026, a sharp gain from the prior close of $56.48. BestStocks flagged the session as a major change for PCVX. The move is tied to price move down. Below, we break down what changed for PCVX, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

PCVX climbed 30.7% to $73.82

PCVX climbed 30.7% in its latest session, moving from $56.48 to $73.82.

Material / EarningsMedium confidence
Rel. volume
11.0×
Extreme
Vs peers
—
No comparable peers
Market cap
$10.7B
NASDAQ Global Select
Analyst target
$124
+67.3% vs price
Price chart
Sep 4 – Oct 5
VEVVFNEE$56$65$74Sep 4Sep 14Sep 21Sep 28Oct 5
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Vaxcyte, Inc. investors

For Vaxcyte, Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Strong 30.7% price move with conviction. Weighing against that: PCVX declined 4.35% intraday to $55.60 on below-average volume (0.47x expected); New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $123.50, implying +67.3% upside from $73.82. BestStocks rates the overall signal quality medium (75/100). With earnings roughly 29 days out, the next report is the most likely near-term test of the move.

PCVX price reaction

PCVX last traded at $73.82, up $17.34 (+30.70%) from the previous close of $56.48. The session traded on 11.0× average volume (extreme), so the move carried above-average conviction. Over the past month the stock has ranged between $56.05 and $73.82, and it currently sits about 100% of the way up that band.

Bullish and bearish analyst opinions on Vaxcyte, Inc. (PCVX)

The consensus analyst price target on Vaxcyte, Inc. (PCVX) is $123.50, 67.3% above the recent $73.82. Over the past 90 days analysts logged 0 upgrades, 2 maintains, and 0 downgrades. Here is how the bullish and bearish cases on PCVX line up.

The bullish case

  • Wall Street's consensus price target of $123.50 implies +67.3% upside from $73.82.
  • The Street's most bullish target is $125.00 (+69.3%).
  • Material positive event.
  • Strong 30.7% price move with conviction.
  • Volume 11.0x average — institutional conviction.

The bearish case

  • PCVX declined 4.35% intraday to $55.60 on below-average volume (0.47x expected).
Bull vs bear balanceBullish Shift
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Oct 5, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $124+67.3%
= 2 maintains
B of A Securities maintained Buy · 2026-09-28
SEC filings watch
8-K2026-10-05
Material event — review for impact
high
8-K2026-09-03
Material event — review for impact
high
10-Q2026-08-05
Quarterly financial results
medium
8-K2026-08-05
Material event — review for impact
high
Peer context
PCVX+30.7%

Previous notable changes for PCVX

Activity2026-10-05+30.7%via globenewswire.com ↗
Vaxcyte, Inc. moved +37.31% intraday from $56.48 to $77.55. Globe Newswire: Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate
Filings2026-10-05+30.7%
PCVX filed a new 8-K on 2026-10-05.
News2026-10-05+30.7%
Vaxcyte Stock Hits New 52-Week High - Here's Why
News2026-10-04
Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate
Upcoming catalysts & outlook
Next earnings
2026-11-03 (est.)
in 29 days
10-Q Filing (est.)
2026-11-04
Medium impact
Thesis shift
Bullish Shift
bullish signal
Risk level
Medium
from change events

Frequently asked questions about PCVX

Why did Vaxcyte, Inc. (PCVX) stock move?

PCVX climbed 30.7% to $73.82. No single company-specific catalyst was confirmed during the move window, and it looks technical.

How much did PCVX stock rise?

PCVX gained 30.70% ($17.34) versus the prior close of $56.48, last trading at $73.82 on 11.0× average volume.

When is Vaxcyte, Inc.'s next earnings date?

PCVX's next earnings report is estimated for 2026-11-03 — about 29 days away.

What is the analyst price target for PCVX?

The consensus analyst price target for PCVX is $123.50, about 67.3% above the current $73.82. Over the past 90 days, analysts recorded 0 upgrades, 2 maintains, and 0 downgrades.

How BestStocks tracks PCVX

This page is generated automatically by BestStocks' change-detection system after price move down was detected and verified against independent data sources. It draws on 20 tracked change events for PCVX, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 5, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataSEC EDGAR filingsCompany news feedsFMP earnings & estimatesAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.